Ecole Nationale Vétérinaire d'Alfort, BioPôle Alfort, Maisons-Alfort, France.
Ecole Nationale Vétérinaire d'Alfort, CHUVA, Service de Médecine Interne, Maisons-Alfort, France.
Vet Comp Oncol. 2022 Dec;20(4):767-777. doi: 10.1111/vco.12848. Epub 2022 Jul 20.
In recent decades, interest in circulating tumour biomarkers is increasing both in human and veterinary oncology. An ideal tumour biomarker would allow early diagnosis of neoplasia, identify it specifically, accurately, establish a prognosis and predict its behaviour, especially regarding different therapeutic solutions. It would also allow to monitor its evolution over time and all this in a non-invasive and inexpensive way. Actually, no biomarkers meeting all of these criteria have been identified in veterinary medicine, particularly due to a lack of specificity of the main protein tumour biomarkers studied to date. However, great hope is currently placed in biomarkers grouped under the name of liquid biopsy, which could prove to be effective tools for common clinical use in the near future. This review gives an update on blood cancer biomarkers studied in dogs, such as ions, proteins, nucleic acids and also circulating cells, of which some might become more prominent in the coming years to help improve the management of animal care.
近几十年来，人们对循环肿瘤生物标志物的兴趣在人类和兽医肿瘤学领域都在不断增加。理想的肿瘤生物标志物将能够实现肿瘤的早期诊断，特异性、准确性地识别肿瘤，建立预后并预测其行为，特别是针对不同的治疗方案。它还能够实现对其随时间推移的演变进行监测，而且所有这些都可以通过非侵入性和廉价的方式来实现。实际上，在兽医领域尚未发现符合所有这些标准的生物标志物，特别是由于迄今为止研究的主要蛋白质肿瘤生物标志物缺乏特异性。然而，目前人们对液体活检这一命名下的生物标志物寄予厚望，因为它们可能在不久的将来成为常见临床应用的有效工具。本文综述了在犬中研究的血液癌症生物标志物，如离子、蛋白质、核酸以及循环细胞，其中一些可能在未来几年变得更加突出，以帮助改善动物护理的管理。
